Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. In the U.S., Aerie developed and markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and the fixed-dose combination Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie has established development operations in Europe and Japan and a global manufacturing facility in Ireland. Aerie is expanding its ophthalmic pipeline with two clinical-stage retina programs in the U.S. and exploration of its proprietary library of small-molecule multi-kinase inhibitors.Visit Aerie online

Aerie is providing an unrestricted education grant to the Advances in Glaucoma Research and Clinical Science Meeting 2019.

As a specialized company dedicated exclusively to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, OTC eye care products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services that contribute to the well-being of patients, their loved ones and consequently to society.

Santen is providing an unrestricted education grant to the Advances in Glaucoma Research and Clinical Science Meeting 2019.

Aerie Pharmaceuticals – Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. In the U.S., Aerie developed and markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and the fixed-dose combination Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie has established development operations in Europe and Japan and a global manufacturing facility in Ireland. Aerie is expanding its ophthalmic pipeline with two clinical-stage retina programs in the U.S. and exploration of its proprietary library of small-molecule multi-kinase inhibitors.Visit Aerie online

Kugler Publications (est. 1974) is an independent publishing company specialized in Oto-Rhino-Laryngology, Ophthalmology, and related fields. Kugler has built a rich experience and solid reputation in publishing books, journals, proceedings and other publications; both in print and electronic. Here at Kugler Publications we aim to keep Simon Kugler’s warm personal touch, and way of doing business based on trust, friendship and long lasting relations incorporated into our everyday company culture. Drop by our booth to browse our publications or discuss your publications ideas.

VISUfarma is a pan-European ophthalmic pharmaceutical company with a clear mission: to bring quality products and global therapeutic innovation to European eye health. Formed in 2016, we are an ambitious and fast growing ophthalmology company, commercialising a broad portfolio of pharmaceutical products and medical devices across Europe and in 20+ countries worldwide through exclusive distributors. We offer a complete portfolio of products in the areas of dry eye, eyelid hygiene, meibomian gland dysfunction (MGD), blepharitis & demodex management, retinal health & food supplements and glaucoma.

World Glaucoma Association (WGA)/World Glaucoma Congress (WGC)

Join us 26–29 June 2020, in Cape Town, South Africa, at the Cape Town International Convention Centre for the 37th World Ophthalmology Congress® (WOC) of the International Council of Ophthalmology, the premier and largest international ophthalmic congress, with over 10,000 delegates expected to attend from over 110 countries.